Literature DB >> 18951320

Management of the middle nasal third in revision rhinoplasty.

Jonathan M Sykes1.   

Abstract

The middle nasal third is often the source of both aesthetic and functional problems with primary rhinoplasty. Weakness of the middle nasal vault can occur from overresection of the upper lateral cartilages or cartilaginous nasal septum, malposition of the upper lateral cartilages, or from secondary scarring from the primary rhinoplasty. These functional and aesthetic problems can be avoided by maintaining an adequate infrastructure to the middle nasal vault. If secondary problems occur in the middle nasal third, precise anatomic reconstruction can be performed in the form of cartilage grafting and/or suture reconstitution. This reconstruction requires an in-depth knowledge of the functional nasal anatomy and the ability to re-create the infrastructure so that it withstands the forces of scarring and wound contraction. This article outlines the anatomy of the middle third of the nose, the conditions that cause secondary middle-third problems, and the surgical management of these deformities.

Entities:  

Mesh:

Year:  2008        PMID: 18951320     DOI: 10.1055/s-0028-1083087

Source DB:  PubMed          Journal:  Facial Plast Surg        ISSN: 0736-6825            Impact factor:   1.446


  3 in total

1.  [Flaring spreader flaps and upper lateral advancement. Modified techniques in the reconstruction of the internal nasal valve].

Authors:  J Wurm; M Kovacevic
Journal:  HNO       Date:  2012-07       Impact factor: 1.284

2.  A Finite Element Model to Simulate Formation of the Inverted-V Deformity.

Authors:  Tjoson Tjoa; Cyrus T Manuel; Ryan P Leary; Rani Harb; Dmitriy E Protsenko; Brian J F Wong
Journal:  JAMA Facial Plast Surg       Date:  2016 Mar-Apr       Impact factor: 4.611

3.  Nasal bone length in Saudi rhinoplasty: a clinical-radiological study.

Authors:  Sami Alharethy; Faris Aldaghri; Tamer A Mesallam; Mohamed Farahat; Manal Ahmed Bukhari
Journal:  Ann Saudi Med       Date:  2014 Jan-Feb       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.